A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age40-90
SponsorHoffmann-La Roche
About this trial
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Eligibility criteria
Qualifiers
Completion of the 52-week treatment period in either parent GB43311 or GB44332
Disqualifiers
Withdrawal of consent and/or premature discontinuation from parent study
Any permanent discontinuation of study drug in parent study
Significant non-compliance in the parent study, specifically defined as missing scheduled visits, per investigator's judgment
Any new diagnosis of asthma according to the Global Initiative for Asthma guidelines or other accepted guidelines since enrolling in the parent study
Trial design
Treatments tested in this trial
- Astegolimab
Treatment groups
2,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov